{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:56Z","timestamp":1786988036367,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejca.2022.12.025","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T11:36:44Z","timestamp":1673264204000},"page":"87-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the \u201cCARACAS\u201d study"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6263-9278","authenticated-orcid":false,"given":"Alessandra A.","family":"Prete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-6339","authenticated-orcid":false,"given":"Paolo","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5380-3144","authenticated-orcid":false,"given":"Vincenzo","family":"Formica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni L.","family":"Frassineti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico C.","family":"Corsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Orciuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bergamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Angerilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaelena","family":"Casagrande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-8989","authenticated-orcid":false,"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ronzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vettore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Salmaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Rasola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1714-1171","authenticated-orcid":false,"given":"Giulia","family":"Maddalena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"del Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6515-5482","authenticated-orcid":false,"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.12.025_bib1","unstructured":"https:\/\/seer.cancer.gov\/statfacts\/html\/anus.html (date of access 25\/February\/2022)."},{"issue":"Suppl 8","key":"10.1016\/j.ejca.2022.12.025_bib2","doi-asserted-by":"crossref","first-page":"S849","DOI":"10.1093\/cid\/civ813","article-title":"Human papillomavirus and genital warts: a review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines","volume":"61","author":"Park","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"17","key":"10.1016\/j.ejca.2022.12.025_bib3","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2013.52.3464","article-title":"Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal","volume":"32","author":"Serup-Hansen","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.12.025_bib4","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.025_bib5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.12.025_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002996","article-title":"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study","volume":"9","author":"Lonardi","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2022.12.025_bib7","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3390\/cancers12092516","article-title":"Evaluation of PD-L1 expression and HPV genotyping in anal squamous cell carcinoma","volume":"12","author":"Wessely","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ejca.2022.12.025_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.32074\/1591-951X-158","article-title":"Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice","volume":"112","author":"Fassan","year":"2020","journal-title":"Pathologica"},{"key":"10.1016\/j.ejca.2022.12.025_bib9","series-title":"R: a language and environment for statistical computing","year":"2019"},{"key":"10.1016\/j.ejca.2022.12.025_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1 \u2013 update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"23","key":"10.1016\/j.ejca.2022.12.025_bib11","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"6257","key":"10.1016\/j.ejca.2022.12.025_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.025_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of Nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2022.12.025_bib14","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.21037\/jtd.2018.11.102","article-title":"Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors","volume":"11","author":"Berland","year":"2019","journal-title":"J Thorac Dis"},{"issue":"10031","key":"10.1016\/j.ejca.2022.12.025_bib15","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ejca.2022.12.025_bib16","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2022.12.025_bib17","article-title":"HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.ejca.2022.12.025_bib18","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1541-7786.MCR-17-0060","article-title":"Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal","volume":"15","author":"Morris","year":"2017","journal-title":"Mol Cancer Res"},{"issue":"4_suppl","key":"10.1016\/j.ejca.2022.12.025_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2020.38.4_suppl.1","article-title":"Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): results from the multicohort, phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.12.025_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ejca.2022.12.025_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1288331","article-title":"Human papilloma virus load and PD-1\/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: rationale for immunotherapy","volume":"6","author":"Balermpas","year":"2017","journal-title":"OncoImmunology"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.025_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004329","article-title":"Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome","volume":"10","author":"Gorris","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.12.025_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.32074\/1591-951X-803","article-title":"PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application","volume":"114","author":"Mastracci","year":"2022","journal-title":"Pathologica"},{"issue":"2","key":"10.1016\/j.ejca.2022.12.025_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/bjc.2015.448","article-title":"Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer","volume":"114","author":"Gilbert","year":"2016","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2022.12.025_bib25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.clon.2021.04.015","article-title":"Multicentre investigation of prognostic factors incorporating p16 and tumour infiltrating lymphocytes for anal cancer after chemoradiotherapy","volume":"33","author":"Wakeham","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"6","key":"10.1016\/j.ejca.2022.12.025_bib26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1634\/theoncologist.2019-0611","article-title":"Prediction of benefit from checkpoint inhibitors in mismatch\u00a0repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes","volume":"25","author":"Loupakis","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2022.12.025_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2010.10.013","article-title":"Genomic instability and cancer: lessons learned from human papillomaviruses","volume":"305","author":"Korzeniewski","year":"2011","journal-title":"Cancer Lett"},{"issue":"suppl_4","key":"10.1016\/j.ejca.2022.12.025_bib28","first-page":"S409","article-title":"Atezolizumab in combination with bevacizumab for patients\u00a0with unresectable\/metastatic anal cancer","volume":"31","author":"Morris","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.12.025_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001395","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus- associated malignancies","volume":"8","author":"Strauss","year":"2020","journal-title":"Journal for ImmunoTherapy of Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:23Z","timestamp":1760733563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923000011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":29,"alternative-id":["S0959804923000011"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the \u201cCARACAS\u201d study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}